Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - academic.oup.com
The introduction of the prostate-specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …
被引用次数：156 相关文章

[引用][C] Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - ideas.repec.org
Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate
Cancer Incidence Trends IDEAS home Advanced search Economic literature: papers …

[引用][C] Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - econpapers.repec.org
EconPapers: Estimating Lead Time and Overdiagnosis Associated with PSA Screening from
Prostate Cancer Incidence Trends EconPapers Economics at your fingertips EconPapers Home …

Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - JSTOR
The introduction of the prostate-specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …

[引用][C] Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

D TELESCA - Biometrics, 2008 - cir.nii.ac.jp
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer
incidence trends | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - pubmed.ncbi.nlm.nih.gov
The introduction of the prostate-specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …

Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - Wiley Online Library
The introduction of the prostate‐specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

D Telesca, R Etzioni, R Gulati - Biometrics, 2007 - europepmc.org
The introduction of the prostate-specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …

Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends.

D Telesca, R Etzioni, R Gulati - Biometrics, 2008 - search.ebscohost.com
The introduction of the prostate-specific antigen (PSA) test has led to dramatic changes in
the incidence of prostate cancer in the United States. In this article, we use information on …

[引用][C] Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends

D TELESCA, R ETZIONI, R GULATI - Biometrics, 2008 - International Biometric Society